Assay Development for High Throughput Screening for Nicotinic Receptor Subunits (R21)

The summary for the Assay Development for High Throughput Screening for Nicotinic Receptor Subunits (R21) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Assay Development for High Throughput Screening for Nicotinic Receptor Subunits (R21)
	CFDA Number:	93.279
	CFDA Description:	Drug Abuse and Addiction Research Programs
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Education Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	RFA-DA-11-007
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Sep 16, 2010
	Creation Date:	Sep 16, 2010
	Original Closing Date for Applications:	Jan 18, 2011
	Current Closing Date for Applications:	Jan 18, 2011
	Archive Date:	Feb 18, 2011
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	$1,500,000
	Federal Grant Award Ceiling:	$150,000
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Grant Description: Purpose. This FOA, issued by the National Institute on Drug Abuse (NIDA), requests applications that propose to develop biological assays that will facilitate the discovery of new molecular probes for investigating the biological function of neuronal nicotinic acetylcholine receptors (nAChRs). Membrane-spanning subunits (alpha and beta) aggregate in pentamers to form various combinations of functional nAChR ion channels. Genetic association studies have implicated variants in the 5-3-4 cholinergic nicotinic receptor subunit gene cluster on chromosome 15q24-25.1 for the risk of nicotine addiction, tobacco dependence, smoking, and lung cancer. Other studies have implicated the 6-subunit in nicotine addiction. This FOA seeks applications proposing to develop biological assays for constitutive receptor combinations involving 3, 5, 6, and/or 4 subunits, suitable ultimately for configuration as high throughput screening (HTS) assays. Once developed, these HTS-ready assays can, and will be expected to be, submitted for screening (http://grants.nih.gov/grants/guide/notice-files/NOT-RM-09-011.html ) by the National Institutes of Health (NIH) Molecular Libraries Production Centers Network (MLPCN) to identify biologically active compounds in a large library of small molecule chemical structures. The chemical structures uncovered through development and use of these assays could then be used for selective ligand development and as possible lead molecules to guide drug discovery in the development of tobacco smoking cessation medications. Mechanism of Support. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism with modifications. Funds Available and Anticipated Number of Awards. Approximately $1.5 million will be available for this FOA in 2011. NIDA anticipates making approximately 5-7 awards in 2011. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/rfa-da-11-007.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • FY12 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1); • Pre-Application for the FY12 NIDA Avant-Garde Award Program for HIV/AIDS Research (X02); • Pre-Application for the 2012 NIDA Translational Avant-Garde Award for Medication Development for the...; • 2012 NIDA Translational Avant-Garde Award for Medication Development for the Treatment of Substance ...; • International Tobacco and Health Research and Capacity Building Program (R01); • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • DRUG ABUSE ASPECTS OF HIV/AIDS AND OTHER INFECTIONS; • EPIDEMIOLOGY OF DRUG ABUSE; • PRESCRIPTION DRUG ABUSE; • MDMA: RESEARCH AREAS NEEDING MORE EMPHASIS